Neoral® rescue therapy in transplant patients with intolerance to tacrolimus
The DOI matches its Crossref record.
Abstract
Background. The calcineurin inhibitors, cyclosporine and tacrolimus, are the mainstay of current immunosuppressive regimens for the prevention of acute rejection in organ transplantation. The choice of the individual agent used often depends on the preference of the Transplant Center and patient type. Adverse effects associated with tacrolimus may impact its clinical utility in many patients. This study characterizes the clinical outcomes of transplant recipients who experienced adverse effects from tacrolimus and were converted to cyclosporine‐microemulsion‐based (Neoral® [cyclosporine, USP] MODIFIED) therapy. Methods. Hepatic or renal allograft recipients unable to maintain adequate immunosuppression with a tacrolimus‐based regimen for reasons of toxicity or efficacy were recruited for this study and converted to cyclosporine‐microemulsion‐based therapy. Data were collected on drug dosing, trough concentrations, and treatment duration, as well as detailed information on tacrolimus‐associated toxicities that prompted rescue with cyclosporine‐microemulsion. Furthermore, clinical and laboratory data related to the clinical course of the patients after conversion to cyclosporine‐microemulsion were recorded for up to 1 yr following conversion. Results. One hundred and fifty‐seven transplant recipients were enrolled in this study. Predominant reasons for discontinuation of tacrolimus were neurotoxicity (55%), diabetes (24%), nephrotoxicity (15%), and gastrointestinal intolerance (24%). Patients frequently had multiple symptoms prompting rescue therapy with cyclosporine‐microemulsion. Over 70% of subjects had improvement or resolution of their tacrolimus‐associated adverse symptoms within 3 months post‐conversion. Acute rejection episodes occurred in 27% of patients converted to cyclosporine‐microemulsion. Conclusions. Cyclosporine‐microemulsion rescue therapy in patients experiencing adverse clinical effects associated with tacrolimus is an effective treatment option which leads to resolution of these adverse effects in the majority of patients, and allows for satisfactory clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nelson, J., Alvey, N., Bowman, L., Schulte, J., Segovia, M. C., McDermott, J., Te, H. S., Kapila, N., Levine, D. J., Gottlieb, R. L., et al. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2716 · Cited by 130
Novel views on new-onset diabetes after transplantation: development, prevention and treatment
Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., de Vries, A. P. J., Porrini, E., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs583 · Cited by 120
Trofe-Clark, J., Brennan, D. C., West-Thielke, P., Milone, M. C., Lim, M. A., Neubauer, R., Nigro, V., & Bloom, R. D. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.07.018 · Cited by 93
Metadata
- Authors
- Abouljoud, M. S., Kumar, M. A., Brayman, K. L., Emre, S., Bynon, J., & for the OLN‐452 Study Group
- Venue
- Clinical Transplantation
- Publisher
- Wiley
- Published
- 2002-05-14
- Volume
- 16
- Issue
- 3
- Pages
- 168-172
- ISSN
- 0902-0063 (ISSN-L)
- 1399-0012
- OpenAlex
- W2096500160
- Cited by
- 52
- References
- 0
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoral® rescue therapy in transplant patients with intolerance to tacrolimus. https://app.cochat.ai/papers/10.1034/j.1399-0012.2002.01054.x
- The paper
- Abouljoud, M. S., Kumar, M. A., Brayman, K. L., Emre, S., Bynon, J., & for the OLN‐452 Study Group. (2002). Neoral® rescue therapy in transplant patients with intolerance to tacrolimus. Clinical Transplantation. https://doi.org/10.1034/j.1399-0012.2002.01054.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.